MedTrace Logo

Vortioxetine for Cancer Patients With Depression: An Observational Study

NCT04253678 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 140

Last updated 2020-02-05

No results posted yet for this study

Summary

The purpose of this observational antidepressant study is to determine the efficacy of vortioxetine on depression and cognitive function, and elucidate its potential effects on quality of life in patients with cancer (of any origin). We hypothesise that given its unique mechanism of action as a multimodal serotonin modulator, vortioxetine is set to achieve the above goals while maintaining a favourable side effect profile.

Conditions

Interventions

DRUG

Vortioxetine

Flexible dosing from 5mg to 20mg based on attending psychiatrist's discretion

Sponsors & Collaborators

  • University of Malaya

    lead OTHER

Principal Investigators

  • Chong Guan Ng · UMMC

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-12
Primary Completion
2020-07-31
Completion
2020-07-31
FDA Drug
Yes

Countries

  • Malaysia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04253678 on ClinicalTrials.gov